Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis-Reference-Cited by-同舟云学术

Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis

Published:2024-03 Issue:2 Volume:11 Page:
ISSN:2332-7812
Container-title:Neurology Neuroimmunology & Neuroinflammation
language:en
Short-container-title:Neurol Neuroimmunol Neuroinflamm

Author:

Androdias Géraldine¹,Noroy Louise¹,Psimaras Dimitri¹^ORCID,Birzu Cristina¹^ORCID,Pelletier Jean¹^ORCID,Beigneux Ysoline¹,Branger Pierre¹^ORCID,Ciron Jonathan¹^ORCID,Dananchet Yannick¹,Depaz Raphael¹,Froment Tilikete Caroline¹,Gignoux Laurence¹,Grosset-Janin Clara¹,Joubert Bastien¹^ORCID,Kerschen Philippe¹^ORCID,Kwiatkowski Arnaud¹,Lebrun-Frenay Christine¹^ORCID,Maillart Elisabeth¹^ORCID,Maureille Aurelien¹,Nicolas Philippe¹^ORCID,Roux Thomas¹,Marignier Romain¹^ORCID,Vukusic Sandra¹^ORCID,

Affiliation:

1. From the Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation (G.A., P.N., R.M., S.V.), Centre de Ressources, Recherche et Compétence sur la Sclérose en Plaques et Fondation Eugène Devic EDMUS pour la Scléros; Ramsay Santé (G.A., L.G.), Clinique de la Sauvegarde, Lyon; Centre Hospitalier de Valence (L.N.), Service de Neurologie, Valence, France; Sorbonne Université (D.P., C.B.), Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Link

https://www.neurology.org/doi/pdfdirect/10.1212/NXI.0000000000200202

Reference14 articles.

2. The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease

3. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives

4. CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis

5. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurologic outcomes in people with multiple sclerosis treated with immune checkpoint inhibitors for oncologic indications;2024-06-13

2. Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis;Neurology Neuroimmunology & Neuroinflammation;2024-05

3. Central nervous system adverse events of immune checkpoint inhibitors;Current Opinion in Neurology;2024-03-14